header logo image


Page 517«..1020..516517518519..530540..»

Diabetic Peripheral Neuropathy Market is Anticipated to Increase Owing to a Rich and Robust Pipeline – Press Release – Digital Journal

June 3rd, 2020 1:46 pm

"Diabetic Peripheral Neuropathy Market"

According to DelveInsight, the Diabetic Peripheral Neuropathy Market in 7MM was found to be approximately USD 2,275.52 Million in 2017 and is set to increase by 2030.

Geography Covered

Study Period: 20172030

Diabetic Peripheral Neuropathy Disease Overview

Diabetic peripheral neuropathy (DPN) also known Distal symmetric polyneuropathy (DSPN) is defined as the symptoms and/or signs of peripheral nerve dysfunction and nerve damage in diabetic patients after the exclusion of other causes. It is a predominantly sensory neuropathy with autonomic nervous system involvement, although there are often motor features with advancing disease.

As per the American Diabetes Association, most common among diabetic neuropathies are chronic DPN, accounting for about 75% of the diabetic neuropathies.

Diabetic Peripheral Neuropathy Epidemiology

DelveInsights estimations suggests the total prevalent cases of Diabetic Peripheral Neuropathy in the 7MM was found to be approximately 25,332,829 in 2017.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalence of Diabetic Peripheral Neuropathy in 7MM, Gender-Specific Prevalence of Diabetic Peripheral Neuropathy in 7MM, Total Diagnosed Prevalence of Painful Diabetic Peripheral Neuropathy in 7MM), scenario of Total Diagnosed Prevalence of Diabetic Peripheral Neuropathy in 7MM in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 20172030.

Visit to know more about the report: https://www.delveinsight.com/report-store/diabetic-peripheral-neuropathy-market

Diabetic Peripheral Neuropathy Market: Treatment and Emerging Therapies

The rising global burden of diabetes is spurring an increase in the prevalence of diabetic neuropathy and neuropathic pain. At present, there are no FDA-approved pathogenetic therapies for DPN and the efficacy of treatments for painful DPN is limited.

The management of pain remains the key aspect of symptom treatment for DPN. The current medications fall into categories, such as antidepressants, anticonvulsants, topical agents and opioids. Antidepressants are further divided into selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCA) group.

Treatments currently approved by both FDA and EMA for pain associated with DPN includepregabalin, duloxetine, and extended-release tapentadol and capsaicin 8% patch. However, no treatments have been approved for the prevention or reversal of DPN.

According to DelveInsight, the Diabetic Peripheral Neuropathy Market in 7MM was found to be approximately USD 2,275.52 Million in 2017 and is set to increase by 2030.

Request for sample pages: https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-market

Of the emerging therapies, the most anticipated product to get launched is VM202 Apart from this, other products include VM202 (Helixmith), NYX-2925 (Aptinyx), WST-057 (4% pirenzepine) WinSanTor, Inc.), Ricolinostat (Regenacy Pharmacuticals), NRD.E1 (Novaremed Ltd.), Ebranopadol (Grnenthal GmbH), GRC 17356 (Glenmark Pharmaceuticals), and others are also expected to enter the market by 2030 as effective therapies.

The key pharma players working in Diabetic Peripheral Neuropathy Market are:

1. Helixmith,

2. Aptinyx

3. WinSanTor, Inc

4. Regenacy Pharmacuticals

5. Ichnos Science

6. Novaremed

7. Grnenthal GmbH

8. Glenmark Pharmaceuticals

9. AstraZeneca

10. Angelini

And many others

Diabetic Peripheral Neuropathy Report Insights

Table of Contents

1. Key Insights

2. Executive summary

3. Diabetic Peripheral Neuropathy Market Overview at a Glance

4. Diabetic Peripheral Neuropathy Epidemiology and Market Methodology

5. Diabetic Peripheral Neuropathy Disease Background and Overview

6. Diabetic Peripheral Neuropathy Epidemiology and Patient Population

7. Diabetic Peripheral Neuropathy Treatment and Management

8. Diabetic Peripheral Neuropathy Unmet needs

9. Diabetic Peripheral Neuropathy Marketed Drugs

10. Diabetic Peripheral Neuropathy Emerging drugs

11. Diabetic Peripheral Neuropathy Market Size

12. Diabetic Peripheral Neuropathy Reimbursement policies

13. Diabetic Peripheral Neuropathy Market Drivers

14. Diabetic Peripheral Neuropathy Market Barriers

15. SWOT Analysis

16. KOL Views

17. Diabetic Peripheral Neuropathy Case Report

18. A Case Report of Diabetic Peripheral Neuropathy

19. Bibliography

20. Appendix

21. Diabetic Peripheral Neuropathy Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.

Browse through our vast repository

Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Vinita Rakheja Email: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: http://www.delveinsight.com/

See more here:
Diabetic Peripheral Neuropathy Market is Anticipated to Increase Owing to a Rich and Robust Pipeline - Press Release - Digital Journal

Read More...

Diabetic Peripheral Neuropathy Market is Expected to Increase with a CAGR of 12% for the Study Period of 2017-2030: DelveInsight – PRNewswire

June 3rd, 2020 1:46 pm

LAS VEGAS, June 2, 2020 /PRNewswire/ -- Diabetic Peripheral Neuropathy Market will increase because of the rising global burden of diabetes that is driving prevalence of diabetic neuropathy, advancement in early diagnosis as well as launch of the promising therapies which will positively impact DPN market.

DelveInsight added a new report titled "Diabetic Peripheral Neuropathy MarketInsights, Epidemiology, and Market Forecast-2030" to its portfolio.

Key Highlights from Diabetic Peripheral Neuropathy Market report are:

Request for sample pages to know more onDiabetic Peripheral Neuropathy Epidemiology and Market Forecast

Diabetic Peripheral Neuropathy is a painful condition that is caused by nerve damage from diabetes. It is a common prevalent complication in neurological damage of Type 1 and Type 2 diabetes.

There is a huge patient population pool affected by the disease; the Diabetic Peripheral Neuropathy market report covers the disease epidemiology that is segmented into Total Diagnosed Prevalent Cases of DPN, Total Prevalent Cases of Painful DPN and Gender-specific Prevalent cases of DPN in the 7MM from 2017 to 2030.

The total Painful Diabetic Peripheral Neuropathy Prevalent Cases were 3,857,945 in the United States in 2020. Also, females are more affected by the disease as compared to males for Diabetic Peripheral NeuropathyPrevalent in the US in 2020.

Click here to know more onDiabetic Peripheral Neuropathypipeline

Among the 7MM, the US accounts for 58% of the overall market size of DPN. Among the EU-5 countries, Germany accounts for the highest market size for DPN. Diabetic Peripheral Neuropathy market has a diverse pipeline with several promising therapies. Also, Gene therapy has been developed for DPN pain management. Of the emerging therapies, the most anticipated product to get launched is VM202 Apart from this, other products include VM202 (Helixmith), NYX-2925 (Aptinyx), WST-057 (4% pirenzepine) (WinSanTor, Inc.), Ricolinostat (Regenacy Pharmacuticals), NRD.E1 (Novaremed Ltd.), Cebranopadol (Grnenthal GmbH), GRC 17356 (Glenmark Pharmaceuticals), and others are also expected to enter the market by 2030 as effective therapies. The potential launch of these emerging drugs will aid in overall market growth. There are a couple of market drivers which will be driving the market. One such factor will be an early diagnosis of the DPN because of the advancements happening in the DPN diagnostic approaches. As the patient pool for diabetic peripheral neuropathy is quite large, and there is no treatment for reversal of disease, this indication withholds a plethora of opportunities for drug development companies. No doubt that the clinical pipeline contains a large number of drugs; however, previously multiple clinical trial failures gave a setback and limited the research and development in the DPN domain. So far it has been clear that path traversed is not easy in DPN research as the long-term clinical trials and low success rate in meeting the clinical endpoints may become threats for the investors to fund further.

There aremany key players robustly involved in developing potential drugs and they are a ray of hopefor DPN patients such as:1. VM2022. NYX-29253. WST-0574. Ricolinostat5. ISC 175366. NRD135S.E17. Cebranopadol8. GRC 173569. MEDI735210. Trazodone/GabapentinAnd many others

The key players involved in Diabetic Peripheral Neuropathy market are:1. Helixmith2. Aptinyx3. WinSanTor, Inc4. Regenacy Pharmacuticals5. Ichnos Science6. Novaremed7. Grnenthal GmbH8. Glenmark Pharmaceuticals9. AstraZeneca10. AngeliniAnd many others

The reasons for buying Diabetic Peripheral Neuropathy market report:

Table of contents

1. Key Insights

2. Executive summary

3. Diabetic Peripheral Neuropathy Market Overview at a Glance

4. Diabetic Peripheral Neuropathy Epidemiology and Market Methodology

5. Diabetic Peripheral Neuropathy Disease Background and Overview

6. Diabetic Peripheral Neuropathy Epidemiology and Patient Population

6.1. Key Findings

6.2. Total Diagnosed Prevalent cases of Diabetic Peripheral Neuropathy in 7MM

6.3. United States

6.4. EU5

6.5. Germany

6.6. France

6.7. Italy

6.8. Spain

6.9. United Kingdom

6.10. Japan

7. Diabetic Peripheral Neuropathy Treatment and Management

8. Diabetic Peripheral Neuropathy Unmet need

9. Diabetic Peripheral Neuropathy Marketed Drugs

9.1. Key cross competition

9.2. Qutenza: Grnenthal

9.3. Tarlige: Daiichi Sankyo

10. Diabetic Peripheral Neuropathy Emerging drugs

10.1. Key cross competition

10.2. VM202: Helixmith

10.3. NYX-2925: Aptinyx

10.4. WST-057: WinSanTor

10.5. Ricolinostat: Regenacy Pharmaceuticals

10.6. Cebranopadol: Grnenthal

10.7. ISC 17536: Ichnos Science

10.8. NRD135S.E1: Novaremed

10.9. MEDI7352: AstraZeneca

10.10. Trazodone/Gabapentin: Angelini

11. Diabetic Peripheral Neuropathy Market Size

11.1. Key Findings

11.2. Total Market Size of Painful Diabetic Peripheral Neuropathy in 7MM

11.3. Diabetic Peripheral Neuropathy Market Outlook: 7 MM

11.4. United States

11.5. EU5

11.6. Germany

11.7. France

11.8. Italy

11.9. Spain

11.10. United Kingdom

11.11. Japan

12. Diabetic Peripheral Neuropathy Reimbursement policies

13. Market Drivers

14. Market Barriers

15. SWOT Analysis

16. KOL Views

17. Diabetic Peripheral Neuropathy Case Report

18. A Case Report of Diabetic Peripheral Neuropathy

19. Bibliography

20. Appendix

21. Diabetic Peripheral Neuropathy Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

Request a WebEx Demo to get a walk-through of the Diabetic Peripheral Neuropathy Market Report:https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-market

Related Reports:

Diabetic Peripheral Neuropathy Epidemiology Forecast-2030 report delivers an in-depth understanding of the disease, historical, forecasted epidemiology trends of DPN in the 7 MM.

Diabetic Peripheral Neuropathy Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Diabetic Peripheral Neuropathy market.

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.

Contact us:

Shruti Thakur[emailprotected]+91-9650213330DelveInsight

SOURCE DelveInsight Business Research, LLP

More here:
Diabetic Peripheral Neuropathy Market is Expected to Increase with a CAGR of 12% for the Study Period of 2017-2030: DelveInsight - PRNewswire

Read More...

Updates on Auditory Neuropathy Spectrum Disorder : The Hearing Journal – LWW Journals

June 3rd, 2020 1:46 pm

Auditory neuropathy was first described in 1996 by Arnold Starr, MD, and colleagues as a hearing impairment that, by behavioral and physiological testing, were compatible with a disorder of the auditory portion of the eighth cranial nerve.1 Since then, research has found notable hallmarks of normal outer hair cell function in the presence of severely abnormal or absent auditory brainstem evoked potentials. When measurable, speech discrimination scores are proportionally lower than expected for the degree of hearing loss, complementing a patient's hearing difficulty (e.g., I can hear sound but can't understand speech, especially in noise). Also, a host of neurological, audiological, and clinical features and findings reveals a variety of causes, genotypes and phenotypes, comorbidities, and auditory consequences. The desynchrony created by auditory neuropathy impairs neural processing, thereby resulting in a series of perceptual disadvantages and compromiseand to various degrees, disabling communication and auditory scene analysis. Whether occuring from a peripheral or a central site, the effects of temporal discord are universal: Auditory temporal processing determines our understanding of speech, our appreciation of music, being able to localize a sound source, and to listen to a person in a noisy crowd.2

Auditory system delineating the inner hair cells (sensory), pre- and postsynaptic portions (synapse), and the spiral ganglion and auditory nerve (neural). Cochlear implantation bypasses the sensory and synaptic portions providing a time-locked signal to the neural partition.6 Health loss, research, neuropathy.

Since the discovery of auditory neuropathy, researchers have described various sites of the lesion along the neural pathway. Auditory neuropathy is a condition of abnormal neural encoding of acoustic signals in the presence of normal sensory transduction and amplification properties of the outer hair cells.3 Potential disorders and sites of lesions include (1) presynaptic disorders affecting inner hair cells and ribbon synapses; (2) postsynaptic disorders affecting unmyelinated auditory nerve dendrites; (3) postsynaptic disorders affecting auditory ganglion cells and their myelinated axons and dendrites; and (4) central neural pathway disorders affecting the auditory brainstem.4 In some cases, auditory neuropathy may include brainstem connections such as those reported in individuals with multiple brainstem neuropathies.5 These structures are divided into three primary partitions responsible for encoding sound: sensory, synaptic, and neural (Fig. 1).6

Fortunately, advancements in auditory electrophysiology and psychophysical tests have made the identification of the site of lesion and functionality more available to clinical practice. These tools have greatly improved diagnosis, treatment selection, and outcome prediction. Having a basic understanding of this complex topic is useful for audiologists and ENT physicians because auditory neuropathy spectrum disorders (ANSDs) occur in children, adults, and seniors due to aging, noise exposure, trauma, and disease. Take note of these pearls of wisdom that will aid in evaluating, diagnosing, and discussing hearing loss and treatments with patients of all ages.

Research highlights relevant to audiology practices include notable information on ANSD prevalence, causations, symptoms, evaluation, testing, and treatments.

PREVALENCE. One in 7,000 neonates evaluated through newborn hearing screening has been found to have an abnormal auditory nerve function.4 ANSD is estimated to occur in one in 10 children with permanent hearing loss.7 Studies suggest that a considerable number of cases may occur in the well-baby population since newborn hearing screenings are typically based on otoacoustic emissions (OAEs)8 rather than auditory brainstem response (ABR)7 or simultaneous testing.

The incidence of patients with auditory neuropathy or cochlear synaptopathy9 in the general population is unknown. However, 10 percent of patients seen at Massachusetts Eye and Ear complain of hearing difficulty in the presence of clinically normal hearing,10 suggesting that ANSD and central auditory processing disorder (CAPD) evaluations should be considered for this population.

CAUSATION. Syndromic and nonsyndromic disorders cause auditory neuropathy through synaptic and neural pathways. Auditory neuropathy varies by etiology, onset age, site of lesion, auditory behavior, and the presence or absence of other peripheral neuropathies.11 Prematurity, low birth weight, hyperbilirubinemia, anoxia, otoferlin gene mutations, Waardenburg's syndrome, Charcot-Marie-Tooth disease (hereditary motor and sensory neuropathy), ototoxic drugs, infection, and cranial nerve hypoplasia, among others, have been reported as risk factors. Genetic disorders account for most cases, especially in children. A mild head injury can cause cranial nerve injury, including an injury to the eighth nerve, although this is less frequent.12

Auditory synaptopathy impairs sound encoding at the synapses between inner hair cells and spiral ganglion neurons.3 Should discrimination difficulty accompany normal hearing sensitivity by standard audiometry (some with ultra-high-frequency hearing loss) and a history of noise exposure or advanced aging, the patient may have cochlear synaptopathy or hidden hearing loss.13

SYMPTOM. Psychophysical testing reveals auditory neuropathy results in perceptual consequences that impair speech discrimination and auditory scene analysis. Unlike cochlear impairments, this condition has a minor effect on loudness, high-frequency pitch discrimination, or localization based on level differences. On the other hand, auditory neuropathy patients have deficiencies in time-based perceptions such as pitch discrimination at low frequencies, temporal integration and modulation detection, binaural beats, masking paradigms, hearing signals in noise, gap detection, and localization using interaural timing.14

Children with this condition may have excellent visual cognition but exhibit poor auditory skills.15 Speech may develop normally or be delayed. Speech discrimination may range from no difficulty in quiet with issues hearing in noise to profound hearing loss in quiet.7

Adults who acquire auditory neuropathy complain of difficulty understanding speech and deafness in background noise. They have difficulty with music perception, sound fading, and localization, and often dislike noise. They may be unemployable for certain jobs, cannot hear well on the telephone, and prefer online jobs and email for communication.

Patients with auditory neuropathy may have constant low-frequency bilateral tinnitus (< 1,000 Hz) with pitch matching at the greatest degree of hearing loss, typically 10 to 15 dB SL.16

In cases of comorbid peripheral neuropathy or a diagnosis of Charcot-Marie-Tooth disease (the most common inherited neurological disease), hearing loss occurs several years before the onset of other symptoms.3

Auditory neuropathy may be progressive as a result of several conditions. These include genetic mutations, mitochondrial disorders, autoimmune anomalies, degenerative changes from aging and noise trauma, toxic metabolic disorders, and nutritional deficits.3

Mutations of the OTOF gene (otoferlin) can express as a transient temperature-sensitive auditory neuropathy, which resolves once the increased body temperature is resolved.17,18 A gene responsible for autosomal dominant auditory neuropathy (AUNA1) was found in a family of European ancestry. The average age of symptom onset was 19 years old.19

EVALUATION. Audiological testing may cover a wide variety of evaluations depending on the patient's age. These may include testing of pure tones, hearing in noise, otoacoustic emissions with and without crossed suppression, acoustic reflexes, cochlear microphonics, summating potentials, ABR, and cortical auditory-evoked potential (CAEP), as well as tympanometry and electrocochleography (ECochG).

Medical evaluation includes an MRI of the inner ears, retrocochlear and brainstem structures, a complete history and genetic analysis, and a physical examination. Audiometric configurations can be downsloping, flat, or high frequency. Low-frequency or reverse curve loss is more prominent, potentially as a result of phase-locking difficulty caused by desynchrony compared to higher frequencies at approximately 2,000 Hz.1

In some cases of auditory neuropathy, patients may have abnormalities in the cochlear microphonic, low amplitude wave V without a wave I, and absent TEOAEs.20 Despite compromised ABRs, CAEPs can often be recorded in ANSD patients. Emerging research highlights the application of CAEP in estimating the behavioral thresholds in this population.21 A slower time constant and recovery allow for better synchrony and reliability.

Vestibular neuropathy may accompany findings of auditory and peripheral neuropathies. Some patients with abnormal caloric responses may be asymptomatic in the presence of peripheral neuropathy.22 The prevalence of at least one vestibular complaint with auditory neuropathy is 20 percent.23 Using the Dizziness Handicap Inventory, the severity of balance complaints is reported as moderate.24

The British Society of Audiology has published comprehensive recommendations for testing young infants who fail newborn screening or considered at risk for ANSD. Testing for this cohort starts with a 4kHz tpABR, followed by another test to identify sensorineural or mixed hearing loss or ANSD, such as a bone conduction ABR, 1 kHz or 0.5 kHz ABR, click ABR, OAE, and/or cochlear microphonics, tympanometry, or stapedial reflexes testing.7 In premature babies, ABR retesting over weeks and months should be conducted to identify those with delayed maturation.

TREATMENT. Goals for newborns with suspected ANSD are to provide appropriate treatment and begin rehabilitation within the first six months. Visual cueing is important in the early stages until the infant's hearing level and diagnosis can be established. Hearing aids, cochlear implants (CI), and rehabilitation options are guided by the locus of the lesion, the severity of synaptic degeneration, concomitant sensory loss, neural competency, and behavioral responses.

Hearing aids are not effective in many cases, although some studies suggest that a trial with amplification, which may include wireless communication, may be recommended based on the patient's degree of hearing loss, age, comorbidities, and behavioral factors. Amplification is typically fit to standard formulas. Enhanced spectral cues and low-pass filtering in the hearing aid prescription are suggested in some cases.7

Regarding CIs, assessment of spiral ganglion health using intraoperative ECochG measurements has become one of the best predictors of CI outcomes. Cochlear implantation results are better when the site of lesion is sensory or synaptic since the CI bypasses these regions to simulate the neural partition (Fig. 1).6 A new hypothesis suggests that binaural cues improve perception in noise. Screening for residual binaural sensitivity might be important when evaluating a patient with AN's candidacy for hearing aids and/or cochlear implants.25

Based on CAEP testing, children more likely show maturation effects within six months and age-appropriate responses when CIs are fitted under the age of two.26

Thoughts on something you read here? Write to us at HJ@wolterskluwer.com

Abdala C, Sininger YS, Starr A (2000). Distortion product otoacoustic emission suppression in subjects with auditory neuropathy, Ear Hear, Dec; 21(6), 542-553. DOI:10.1097/00003446-200012000-00002

CDC (2017). Hearing loss in children; 2017 Hearing Screening Summary. Retrieved online. https://www.cdc.gov/ncbddd/hearingloss/2017-data/01-data-summary.html

Jutras B, Russell LJ, Hurteau AM, Chapdelaine M (2003). Auditory neuropathy in siblings with Waardenburg's syndrome, Int J Ped Otorhinolaryngol, Oct; 67(10), 1133-1142. DOI: 10.1016/s0165-5876(03)00200-3

More:
Updates on Auditory Neuropathy Spectrum Disorder : The Hearing Journal - LWW Journals

Read More...

COVID-19 Impact on Peripheral Neuropathy Treatment Market to Witness a Pronounce Growth During 2020-2025, Top key players are Eli Lilly, Johnson &…

June 3rd, 2020 1:46 pm

COVID-19 Impact on Peripheral Neuropathy Treatment Market, Global Research Reports 2020-2021

In 2019, the global COVID-19 Impact on Peripheral Neuropathy Treatment Market size was US$ xx million and it is expected to reach US$ xx million by the end of 2026, with a CAGR of xx% during 2021-2026.

COVID-19 Impact on Peripheral Neuropathy Treatment Market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global COVID-19 Impact on Peripheral Neuropathy Treatment Market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.The Report scope furnishes with vital statistics about the current market status and manufacturers. It analyzes the in-depth business by considering different aspects, direction for companies, and strategy in the industry.

After analyzing the report and all the aspects of the new investment projects, it is assessed the overall research and closure offered. The analysis of each segment in-detailed with various point views; that include the availability of data, facts, and figures, past performance, trends, and way of approaching in the market. The COVID-19 Impact on Peripheral Neuropathy Treatment Market report also covers the in-depth analysis of the market dynamics, price, and forecast parameters which also include the demand, profit margin, supply and cost for the industry.

The report additionally provides a pest analysis of all five along with the SWOT analysis for all companies profiled in the report. The report also consists of various company profiles and their key players; it also includes the competitive scenario, opportunities, and market of geographic regions. The regional outlook on the COVID-19 Impact on Peripheral Neuropathy Treatment Market covers areas such as Europe, Asia, China, India, North America, and the rest of the globe.

In-depth analysis of expansion and growth strategies obtained by Key players and their effect on competition market growth. The research report also provides precise information on your competitors and their planning. All of the above will help you to make a clear plan for top-line growth.

Get sample copy of thisreport @ https://www.lexisbusinessinsights.com/request-sample-133713

Top key players @ Major competitors identified in this market include Eli Lilly, Johnson & Johnson, Novartis, Pfizer, Aptinyx, Regenacy Pharmaceuticals, TEVA Pharmaceutical Industries, Immune Pharmaceuticals, etc.

The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of COVID-19 Impact on Peripheral Neuropathy Treatment Market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.

Global COVID-19 Impact on Peripheral Neuropathy Treatment Market: Regional Segment Analysis

This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they COVID-19 Impact on Peripheral Neuropathy Treatment Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key factors driving the Global COVID-19 Impact on Peripheral Neuropathy Treatment Market?

What are the key market trends impacting the growth of the Global COVID-19 Impact on Peripheral Neuropathy Treatment Market?

What are the challenges to market growth?

Who are the key vendors in the Global COVID-19 Impact on Peripheral Neuropathy Treatment Market?

What are the market opportunities and threats faced by the vendors in the Global COVID-19 Impact on Peripheral Neuropathy Treatment Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

The report includes six parts, dealing with:

1.) Basic information;

2.) The Asia COVID-19 Impact on Peripheral Neuropathy Treatment Market;

3.) The North American COVID-19 Impact on Peripheral Neuropathy Treatment Market;

4.) The European COVID-19 Impact on Peripheral Neuropathy Treatment Market;

5.) Market entry and investment feasibility;

6.) The report conclusion.

All the research report is made by using two techniques that are Primary and secondary research. There are various dynamic features of the business, like client need and feedback from the customers. Before (company name) curate any report, it has studied in-depth from all dynamic aspects such as industrial structure, application, classification, and definition.

The report focuses on some very essential points and gives a piece of full information about Revenue, production, price, and market share.

COVID-19 Impact on Peripheral Neuropathy Treatment Market report will enlist all sections and research for each and every point without showing any indeterminate of the company.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2019-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

Get Complete Brochure @https://www.lexisbusinessinsights.com/request-sample-133713

About Us:

Statistical surveying reports is a solitary goal for all the business, organization and nation reports. We highlight huge archive of most recent industry reports, driving and specialty organization profiles, and market measurements discharged by rumored private distributors and open associations. Statistical surveying Store is the far reaching gathering of market knowledge items and administrations accessible on air. We have statistical surveying reports from number of driving distributors and update our gathering day by day to furnish our customers with the moment online access to our database. With access to this database, our customers will have the option to profit by master bits of knowledge on worldwide businesses, items, and market patterns

Contact Us:

Lexis Business Insights

Aaryan

(Business Development Manager)

US: +1 210 907 4145

APAC: +91 9867799788

6851 N Loop

1604 W San Antonio,

TX 78249

[emailprotected]

http://www.lexisbusinessinsights.com

Go here to read the rest:
COVID-19 Impact on Peripheral Neuropathy Treatment Market to Witness a Pronounce Growth During 2020-2025, Top key players are Eli Lilly, Johnson &...

Read More...

Kannalife, Inc. Appoints Terrence O. Tormey to the Company’s Board of Advisors – GlobeNewswire

June 3rd, 2020 1:46 pm

DOYLESTOWN, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (Kannalife or the Company) (OTCQB: KLFE), a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced today that it has appointed biotechnology and pharmaceutical industry veteran, Terrence O. Tormey, to the Companys Board of Advisors.

Mr. Tormeys most recent position was CEO of Kibow Biotech, a company involved in the development of novel renal care treatment for chronic kidney disease. For over four decades, Mr. Tormey has held numerous C-Level management positions, board seats, and has led successful sales and marketing campaigns with well-known life sciences companies including Wyeth, OMAX Health, Prevention Pharmaceuticals, and McNeil CPC (Johnson & Johnson).

"Its really great to have Terry join our corporate advisory board and team of experts at Kannalife. His experience, vision and extraordinary body of knowledge in the life sciences industry come at a perfect time for us as we start to design our commercialization and distribution plan for Atopidine, said Dean Petkanas, CEO of Kannalife.

I am honored to serve as an advisor to Kannalife. They have remarkable scientists behind the entities in development. These scientists are addressing a most challenging unmet medical need that is pain relief without opioids. Specifically, a treatment for Chemotherapy Induced Peripheral Neuropathy (CIPN), which, when approved, will help improve the lives of hundreds of thousands of patients, Tormey said.

About Kannalife, Inc.Kannalife, Inc. is a biopharmaceutical medchem company focused on the development of proprietary and patented novel, monotherapeutic molecules for patients suffering from unmet medical needs of neurodegenerative disorders - including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE), a disease associated with highly repetitive impact injuries in professional and amateur sports.

Atopidine is Kannalifes novel, patented small molecule that has been shown to have protective and anti-inflammatory properties in pre-clinical testing. The same studies show that it has also outperformed cannabidiol (CBD) in preventing inflammatory responses relevant to UVB-radiation, including cytokines, TNF-a, IL-1b, and IL-6.

KLS-13019 is Kannalifes leading patented, investigational, novel, monotherapeutic product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). Neither KLS-13019 or Atopidine have been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. Their safety and efficacy have not been confirmed by FDA-approved research.

The Company's KLS Family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.

For more information about Kannalife, Inc., visit http://www.kannalife.com and visit the Companys Twitter page at @Kannalife.

Forward-Looking StatementsThis press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the Companys business plan, plan of operations, the viability of the Companys drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

CONTACT:

Public Relations:Andrew Hard, Chief Executive Officer of CMW MediaP: 888-829-0070E: andrew.hard@cmwmedia.com

Investor Relations: Scott Gordon, Managing Director of CORE IRP: 516-222-2560E: scottg@coreir.comwww.coreir.com

View post:
Kannalife, Inc. Appoints Terrence O. Tormey to the Company's Board of Advisors - GlobeNewswire

Read More...

Neuropathy Pain Treatment Market 2020| Global Leading Players, Industry Updates, Future Growth, Business Prospects, Forthcoming Developments And…

June 3rd, 2020 1:46 pm

The market research report published by QYResearch is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Neuropathy Pain Treatment market. It informs readers about key trends and opportunities in the global Neuropathy Pain Treatment market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Neuropathy Pain Treatment market.

Key companies operating in the global Neuropathy Pain Treatment market include , Pfizer, Depomed, Eli Lilly, Endo, Grnenthal Group, Arbor Pharmaceuticals, Neuropathy Pain Treatment

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1436343/global-neuropathy-pain-treatment-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Neuropathy Pain Treatment market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Neuropathy Pain Treatment Market Segment By Type:

, Calcium Channel Alpha 2-delta Ligands, Serotonin-norepinephrine Reuptake Inhibitors, Other

Global Neuropathy Pain Treatment Market Segment By Application:

, Retail Pharmacies, Hospitals, Other

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Neuropathy Pain Treatment market.

Key companies operating in the global Neuropathy Pain Treatment market include , Pfizer, Depomed, Eli Lilly, Endo, Grnenthal Group, Arbor Pharmaceuticals, Neuropathy Pain Treatment

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1436343/global-neuropathy-pain-treatment-market

TOC

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Neuropathy Pain Treatment Revenue1.4 Market Analysis by Type 1.4.1 Global Neuropathy Pain Treatment Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Calcium Channel Alpha 2-delta Ligands 1.4.3 Serotonin-norepinephrine Reuptake Inhibitors 1.4.4 Others1.5 Market by Application 1.5.1 Global Neuropathy Pain Treatment Market Share by Application: 2020 VS 2026 1.5.2 Retail Pharmacies 1.5.3 Hospitals 1.5.4 Others1.6 Coronavirus Disease 2019 (Covid-19): Neuropathy Pain Treatment Industry Impact 1.6.1 How the Covid-19 is Affecting the Neuropathy Pain Treatment Industry 1.6.1.1 Neuropathy Pain Treatment Business Impact Assessment Covid-19 1.6.1.2 Supply Chain Challenges 1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products 1.6.2 Market Trends and Neuropathy Pain Treatment Potential Opportunities in the COVID-19 Landscape 1.6.3 Measures / Proposal against Covid-19 1.6.3.1 Government Measures to Combat Covid-19 Impact 1.6.3.2 Proposal for Neuropathy Pain Treatment Players to Combat Covid-19 Impact1.7 Study Objectives1.8 Years Considered 2 Global Growth Trends by Regions2.1 Neuropathy Pain Treatment Market Perspective (2015-2026)2.2 Neuropathy Pain Treatment Growth Trends by Regions 2.2.1 Neuropathy Pain Treatment Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Neuropathy Pain Treatment Historic Market Share by Regions (2015-2020) 2.2.3 Neuropathy Pain Treatment Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porters Five Forces Analysis 2.3.5 Neuropathy Pain Treatment Market Growth Strategy 2.3.6 Primary Interviews with Key Neuropathy Pain Treatment Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Neuropathy Pain Treatment Players by Market Size 3.1.1 Global Top Neuropathy Pain Treatment Players by Revenue (2015-2020) 3.1.2 Global Neuropathy Pain Treatment Revenue Market Share by Players (2015-2020) 3.1.3 Global Neuropathy Pain Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Neuropathy Pain Treatment Market Concentration Ratio 3.2.1 Global Neuropathy Pain Treatment Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Neuropathy Pain Treatment Revenue in 20193.3 Neuropathy Pain Treatment Key Players Head office and Area Served3.4 Key Players Neuropathy Pain Treatment Product Solution and Service3.5 Date of Enter into Neuropathy Pain Treatment Market3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Neuropathy Pain Treatment Historic Market Size by Type (2015-2020)4.2 Global Neuropathy Pain Treatment Forecasted Market Size by Type (2021-2026) 5 Neuropathy Pain Treatment Breakdown Data by Application (2015-2026)5.1 Global Neuropathy Pain Treatment Market Size by Application (2015-2020)5.2 Global Neuropathy Pain Treatment Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Neuropathy Pain Treatment Market Size (2015-2020)6.2 Neuropathy Pain Treatment Key Players in North America (2019-2020)6.3 North America Neuropathy Pain Treatment Market Size by Type (2015-2020)6.4 North America Neuropathy Pain Treatment Market Size by Application (2015-2020) 7 Europe7.1 Europe Neuropathy Pain Treatment Market Size (2015-2020)7.2 Neuropathy Pain Treatment Key Players in Europe (2019-2020)7.3 Europe Neuropathy Pain Treatment Market Size by Type (2015-2020)7.4 Europe Neuropathy Pain Treatment Market Size by Application (2015-2020) 8 China8.1 China Neuropathy Pain Treatment Market Size (2015-2020)8.2 Neuropathy Pain Treatment Key Players in China (2019-2020)8.3 China Neuropathy Pain Treatment Market Size by Type (2015-2020)8.4 China Neuropathy Pain Treatment Market Size by Application (2015-2020) 9 Japan9.1 Japan Neuropathy Pain Treatment Market Size (2015-2020)9.2 Neuropathy Pain Treatment Key Players in Japan (2019-2020)9.3 Japan Neuropathy Pain Treatment Market Size by Type (2015-2020)9.4 Japan Neuropathy Pain Treatment Market Size by Application (2015-2020) 10 Southeast Asia10.1 Southeast Asia Neuropathy Pain Treatment Market Size (2015-2020)10.2 Neuropathy Pain Treatment Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Neuropathy Pain Treatment Market Size by Type (2015-2020)10.4 Southeast Asia Neuropathy Pain Treatment Market Size by Application (2015-2020) 11 India11.1 India Neuropathy Pain Treatment Market Size (2015-2020)11.2 Neuropathy Pain Treatment Key Players in India (2019-2020)11.3 India Neuropathy Pain Treatment Market Size by Type (2015-2020)11.4 India Neuropathy Pain Treatment Market Size by Application (2015-2020) 12 Central & South America12.1 Central & South America Neuropathy Pain Treatment Market Size (2015-2020)12.2 Neuropathy Pain Treatment Key Players in Central & South America (2019-2020)12.3 Central & South America Neuropathy Pain Treatment Market Size by Type (2015-2020)12.4 Central & South America Neuropathy Pain Treatment Market Size by Application (2015-2020) 13 Key Players Profiles13.1 Pfizer 13.1.1 Pfizer Company Details 13.1.2 Pfizer Business Overview and Its Total Revenue 13.1.3 Pfizer Neuropathy Pain Treatment Introduction 13.1.4 Pfizer Revenue in Neuropathy Pain Treatment Business (2015-2020)) 13.1.5 Pfizer Recent Development13.2 Depomed 13.2.1 Depomed Company Details 13.2.2 Depomed Business Overview and Its Total Revenue 13.2.3 Depomed Neuropathy Pain Treatment Introduction 13.2.4 Depomed Revenue in Neuropathy Pain Treatment Business (2015-2020) 13.2.5 Depomed Recent Development13.3 Eli Lilly 13.3.1 Eli Lilly Company Details 13.3.2 Eli Lilly Business Overview and Its Total Revenue 13.3.3 Eli Lilly Neuropathy Pain Treatment Introduction 13.3.4 Eli Lilly Revenue in Neuropathy Pain Treatment Business (2015-2020) 13.3.5 Eli Lilly Recent Development13.4 Endo 13.4.1 Endo Company Details 13.4.2 Endo Business Overview and Its Total Revenue 13.4.3 Endo Neuropathy Pain Treatment Introduction 13.4.4 Endo Revenue in Neuropathy Pain Treatment Business (2015-2020) 13.4.5 Endo Recent Development13.5 Grnenthal Group 13.5.1 Grnenthal Group Company Details 13.5.2 Grnenthal Group Business Overview and Its Total Revenue 13.5.3 Grnenthal Group Neuropathy Pain Treatment Introduction 13.5.4 Grnenthal Group Revenue in Neuropathy Pain Treatment Business (2015-2020) 13.5.5 Grnenthal Group Recent Development13.6 Arbor Pharmaceuticals 13.6.1 Arbor Pharmaceuticals Company Details 13.6.2 Arbor Pharmaceuticals Business Overview and Its Total Revenue 13.6.3 Arbor Pharmaceuticals Neuropathy Pain Treatment Introduction 13.6.4 Arbor Pharmaceuticals Revenue in Neuropathy Pain Treatment Business (2015-2020) 13.6.5 Arbor Pharmaceuticals Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source15.2 Disclaimer15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Go here to see the original:
Neuropathy Pain Treatment Market 2020| Global Leading Players, Industry Updates, Future Growth, Business Prospects, Forthcoming Developments And...

Read More...

Neuropathy Pain Treatment Market Research Report 2020: Key Players, Applications, Drivers, Trends and Forecast to 2026 – WaterCloud News

June 3rd, 2020 1:46 pm

Others

In addition, the report categorizes product type and end uses as dynamic market segments that directly impact the growth potential and roadmap of the target market. The report highlights the core developments that are common to all regional hubs and their subsequent impact on the holistic growth path of the Neuropathy Pain Treatment market worldwide. Other valuable aspects of the report are the market development history, various marketing channels, supplier analysis, potential buyers and the analysis of the markets industrial chain.

Ask For Discounts @ https://www.marketresearchintellect.com/ask-for-discount/?rid=275286&utm_source=WCS&utm_medium=888

Table of Content

1 Introduction of Neuropathy Pain Treatment Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Market Research Intellect

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Neuropathy Pain Treatment Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Neuropathy Pain Treatment Market, By Deployment Model

5.1 Overview

6 Neuropathy Pain Treatment Market, By Solution

6.1 Overview

7 Neuropathy Pain Treatment Market, By Vertical

7.1 Overview

8 Neuropathy Pain Treatment Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Neuropathy Pain Treatment Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=275286&utm_source=WCS&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Neuropathy Pain Treatment Market Size, Neuropathy Pain Treatment Market Trends, Neuropathy Pain Treatment Market Growth, Neuropathy Pain Treatment Market Forecast, Neuropathy Pain Treatment Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

Follow this link:
Neuropathy Pain Treatment Market Research Report 2020: Key Players, Applications, Drivers, Trends and Forecast to 2026 - WaterCloud News

Read More...

Eisai Announces Updated Results of ENHANCE 1, a Phase 1b/2 Trial Investigating HALAVEN (eribulin mesylate) plus KEYTRUDA (pembrolizumab) in Patients…

June 3rd, 2020 1:46 pm

This open-label, single-arm, multicenter, Phase 1b/2 study enrolled patients with mTNBC who had previously received zero to two systemic therapies for metastatic disease and were stratified by prior number of therapy (Stratum 1 = 0 prior therapies; Stratum 2 = 1-2 prior therapies). As there were no dose-limiting toxicities observed in Phase 1, patients received the recommended Phase 2 dose of eribulin (1.4 mg/m2 intravenously on Day 1 and Day 8) and pembrolizumab (200 mg intravenously on Day 1) of a 21-day cycle. At the time of data cutoff (July 31, 2019), 167 patients were enrolled (of which 149 patients had confirmed PD-L1 status). The primary objectives were safety and objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by independent imaging review. Secondary objectives included progression free survival (PFS), overall survival (OS), duration of response (DOR) and clinical benefit rate (CBR) overall and by PD-L1 status. Previous findings from ENHANCE 1 were presented during a Spotlight Session at the San Antonio Breast Cancer Symposium (SABCS) in 2017.

Updated findings presented during ASCO20 showed:

The most common treatment-emergent adverse events were fatigue (66%), nausea (57%), peripheral sensory neuropathy (41%), alopecia (40%), and constipation (37%). No deaths were considered treatment related. The most common possibly immune-related TEAEs for pembrolizumab (occurring in >3% of patients) were hypothyroidism (18%), pneumonitis (11%), hyperthyroidism (8%) and infusion-related reaction (3%).

"Treatment options for metastatic triple-negative breast cancer remain limited, despite advances in the field," said Dr. Takashi Owa, Vice President, Chief Medicine Creation Officer and Chief Discovery Officer, Oncology Business Group at Eisai. "As a human health care company, we are committed to addressing cancers that remain difficult to treat, and this is evident in our ongoing investigation in triple-negative disease. As long as unmet needs exist, Eisai will persist in our efforts to innovate for patients."

This release discusses an investigational use for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.

Previously, data from ENHANCE 1 was reported at the San Antonio Breast Cancer Symposium in 2016 and 2017.

The study is being conducted under an existing clinical trial collaboration agreement between Eisai and Merck.

About HALAVEN(eribulin mesylate) InjectionHALAVEN (eribulin mesylate) injection is indicated for the treatment of patients with metastatic breast cancer (mBC) who have previously received at least 2 chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.

Discovered and developed by Eisai, eribulin is a synthetic analog of halichondrin B, a natural product that was isolated from the marine spongeHalichondria okadai. First in the halichondrin class, eribulin is a microtubule dynamics inhibitor. Eribulin is believed to work primarily via a tubulin-based mechanism that causes prolonged and irreversible mitotic blockage, ultimately leading to apoptotic cell death. Additionally, in preclinical studies of human breast cancer, eribulin demonstrated complex effects on the tumor biology of surviving cancer cells, including increases in vascular perfusion resulting in reduced tumor hypoxia, and changes in the expression of genes in tumor specimens associated with a change in phenotype, promoting the epithelial phenotype, opposing the mesenchymal phenotype. Eribulin has also been shown to decrease the migration and invasiveness of human breast cancer cells.

Important Safety Information

Warnings and Precautions

Neutropenia: Severe neutropenia (ANC <500/mm3) lasting >1 week occurred in 12% of patients with mBC. Febrile neutropenia occurred in 5% of patients with mBC and 2 patients (0.4%) died from complications. Patients with mBC with elevated liver enzymes >3 ULN and bilirubin >1.5 ULN experienced a higher incidence of Grade 4 neutropenia and febrile neutropenia than patients with normal levels. Monitor complete blood cell counts prior to each dose, and increase the frequency of monitoring in patients who develop Grade 3 or 4 cytopenias. Delay administration and reduce subsequent doses in patients who experience febrile neutropenia or Grade 4 neutropenia lasting >7 days.

Peripheral Neuropathy: Grade 3 peripheral neuropathy occurred in 8% of patients with mBC (Grade 4=0.4%) and 22% developed a new or worsening neuropathy that had not recovered within a median follow-up duration of 269 days (range 25-662 days). Neuropathy lasting >1 year occurred in 5% of patients with mBC. Patients should be monitored for signs of peripheral motor and sensory neuropathy. Withhold HALAVEN in patients who experience Grade 3 or 4 peripheral neuropathy until resolution to Grade 2 or less.

Embryo-Fetal Toxicity: HALAVEN can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with HALAVEN and for at least 2 weeks following the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with HALAVEN and for 3.5 months following the final dose.

QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. Correct hypokalemia or hypomagnesemia prior to initiating HALAVEN and monitor these electrolytes periodically during therapy. Avoid in patients with congenital long QT syndrome.

Adverse ReactionsIn patients with mBC receiving HALAVEN, the most common adverse reactions (25%) were neutropenia (82%), anemia (58%), asthenia/fatigue (54%), alopecia (45%), peripheral neuropathy (35%), nausea (35%), and constipation (25%). Febrile neutropenia (4%) and neutropenia (2%) were the most common serious adverse reactions. The most common adverse reaction resulting in discontinuation was peripheral neuropathy (5%).

Use in Specific PopulationsLactation: Because of the potential for serious adverse reactions in breastfed infants from eribulin mesylate, advise women not to breastfeed during treatment with HALAVEN and for 2 weeks after the final dose.

Hepatic and Renal Impairment: A reduction in starting dose is recommended for patients with mild or moderate hepatic impairment and/or moderate or severe renal impairment.

For more information about HALAVEN, clickherefor the full Prescribing Information.

HALAVEN is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.

About Eisai Eisai is a leading global research and development-based pharmaceutical company headquartered in Japan, with approximately 10,000 employees worldwide. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. We strive to realize our hhc philosophy by delivering innovative products in therapeutic areas with high unmet medical needs, including Oncology and Neurology. In the spirit of hhc, we take that commitment even further by applying our scientific expertise, clinical capabilities and patient insights to discover and develop innovative solutions that help address society's toughest unmet needs, including neglected tropical diseases and the Sustainable Development Goals.

For more information about Eisai, please visit http://www.eisai.com (for global), us.eisai.com(for U.S.) or http://www.eisai.eu (for Europe, Middle East, Africa), and connect with us on Twitter (U.S.and global) and LinkedIn(for U.S.).

SOURCE Eisai Inc.

http://www.eisai.com

Go here to see the original:
Eisai Announces Updated Results of ENHANCE 1, a Phase 1b/2 Trial Investigating HALAVEN (eribulin mesylate) plus KEYTRUDA (pembrolizumab) in Patients...

Read More...

Medical Foods Market Predicted to Accelerate the Growth by 2017-2025 – Medic Insider

June 3rd, 2020 1:46 pm

Global Medical Foods Market: Overview

One of the key factors boosting the growth of the global medical foods market is the rising awareness among the people regarding medical foods. The rising focus of the regulatory bodies on the manufacturing and labelling of medical foods will also be a key factor fuelling the growth of the medical foods market. In addition to this, the high focus by manufacturers on developing disease-specific formulas effective patients nutrition or diet care are also anticipated to result in the growth of the global medical foods market.

The report also enlists various factors which are anticipated to pose a challenge for the growth of the market. The current trends in the market and those that are anticipated to shape the future of the market have been discussed in detail in the report.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=2558

By product, the medical food market is segmented into powder, pill, and others. Of these the powder segment has held a key share in the market as many medical food products are manufactured in powdered form and consumed in a semi solid or liquid form. By application, the global medical foods market is segmented into depression, diabetic neuropathy, ADHD, Alzheimers disease, and nutritional deficiency. Of these, diabetic neuropathy has been accounting for key shares within the market. The risk of neuropathy is boosted with age, diet changes, and unhealthy lifestyle.

In the years to come, it is anticipated that the nutritional deficiencies segment will develop a strong CAGR, as patients being treated for ADHD, autoimmune diseases, and cancer are likely to have high nutritional requirements, which is subsequently anticipated to boost the demand for medical foods.

Global Medical Foods Market: Snapshot

The global medical foods market has become increasingly important in the healthcare sector in recent years due to the rising awareness about its importance in complementing the treatment. Medical food comprises diets designed specifically to overcome the nutritional deficiencies caused by some diseases or to fulfill the specific dietary needs in the management of some diseases. The global medical foods market is likely to receive steady support from the healthcare sector in the coming years due to the rising prevalence of diseases such as Alzheimers among the elderly and ADHD among children, as these diseases are among the prime diseases that necessitate specific diet plans.

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=2558

Global Medical Foods Market: Key Trends

The rising geriatric population is a major driver for the global medical foods market. Old people are more likely to develop nutritional disorders as well as to fall prey to other diseases that affect their ability to absorb nutrients from their diet. Nutrition deficiency disorders are also more common among the geriatric demographic than in other patient classes, leading to the geriatric population becoming a key consumer segment for the global medical foods market.

The increasing prevalence of diabetes across the world is another key driver for the global medical foods market. Diabetic neuropathy is the leading application of the global medical foods market and is likely to retain dominance in the coming years. Diabetic neuropathy is becoming common among diabetic patients due to their often unhealthy lifestyles, with close to three-quarters of all diabetes likely to also suffer from some form of neuropathy. This is a key driver for the global medical food market, as the rising prevalence of diabetes in emerging regions has, in conjunction with the rising investment in the healthcare sector, created a conducive environment for growth of the market.

The rising prevalence of ADHD among children is also likely to remain a key driver for the global medical foods market. The growing prevalence of the disease has led to intensive research into its causation and treatment. The role of nutrition in the management of psychological problems such as ADHD has thus come under the scanner. On the opposite end of the spectrum, the rising prevalence of neurodegenerative conditions among the geriatric population is also likely to remain a key driver for the global medical foods market in the coming years.

Global Medical Foods Market: Market Potential

The global medical foods market is likely to witness a steady shift towards pills and away from powders. While powders can be easily mixed with various types of food, many patients dont enjoy their taste. This has led to pills becoming a preferred mode of delivery for many, and are thus likely to rise in demand in the global medical foods market in the coming years.

Apart from leading diseases such as diabetic neuropathy and Alzheimers, other diseases such as phenylketonuria (PKU) are also likely to come under the ambit of the medical food market in the coming years. In April 2017, PKU Sphere, a new medical food for patients of PKU was launched. PKU Sphere is claimed to contain a balanced mix of amino acids and glycomacropeptide, a protein essential for patients of PKU, who cant digest phenylalanine and have to fulfill their protein requirements in alternate ways.

Global Medical Foods Market: Geographical Dynamics

North America is likely to remain the leading regional contributor to the global medical foods market in the coming years due to the ready availability of advanced healthcare technology and a solid database regarding the dietary needs of patients suffering from various diseases. The rising prevalence of diabetes in North America, due primarily to the unhealthy lifestyle practiced by citizens in developed countries such as the U.S., is also likely to be crucial for the medical foods market in North America in the coming years.

Global Medical Foods Market: Competitive Dynamics

The leading players in the global medical foods market include Abbott, Fresenius Kabi AG, Targeted Medical Pharma Inc., Danone, and Primus Pharmaceuticals Inc. The steady support to development of sophisticated disease-specific formulas is likely to benefit the medical foods market in the coming years.

Read Comprehensive Overview of Report @https://www.tmrresearch.com/medical-foods-market

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Originally posted here:
Medical Foods Market Predicted to Accelerate the Growth by 2017-2025 - Medic Insider

Read More...

Obesity only preadmission factor to influence COVID-19 outcomes in diabetes – medwireNews

June 2nd, 2020 8:46 pm
  1. Obesity only preadmission factor to influence COVID-19 outcomes in diabetes  medwireNews
  2. COVID-19 provides opportunity for digital innovation in diabetes care  Health Europa
  3. One in 10 hospitalized COVID-19 patients with diabetes die by day seven, study finds  MinnPost
  4. 10% With Diabetes Hospitalized for COVID-19 Die Within a Week  Medscape
  5. COVID-19 Comorbidities: Diabetes is Among the Top Three  Diabetes In Control
  6. View Full Coverage on Google News

See the rest here:
Obesity only preadmission factor to influence COVID-19 outcomes in diabetes - medwireNews

Read More...

Mother of 2 with diabetes gets coronavirus and is left with brain damage – FOX 2 Detroit

June 2nd, 2020 8:46 pm

FOX 2 - A Taylor woman's life has been changed forever because of COVID-19 and now she is in dire need of help. She will need to be moved to an acute rehab facility but not many are willing to take here because she had the virus.

"It is a lot, it is really overwhelming," said Wanavia Wilson. "Some nights I just cried all night, I didn't know what to do."

A Taylor woman's life has been changed forever because of COVID-19 and now she is in dire need of help.

Wanavia Wilson has been by her daughter's side since mid-May. Shantel Wilson, a 25-year-old mother of two small children, suffers from Type 1 diabetes. On May 12th she went to sleep and her blood sugar dropped to dangerous levels.

"When she is awake she notices the symptoms, the shakiness, the dizziness and she'll go and tested herself and eat something if it is low, because she was sleeping when it happened. She just kept sleeping and never woke up. (She was in a coma) for four days."

Doctors told her mother that Shantel suffered severe brain damage. Although she didn't have any symptoms, a routine test also revealed Shantel had COVID-19, which may have caused her blood to drop. She is now at Beaumont Farmington.

"She needs neurological therapies, speech therapy, physical therapy and occupational therapy," Wanavia said. "Because her sugar was low for an undetermined amount of time, they said they said going that long caused significant damage to both sides of her brain and it affecting her speech and her behaviors. So right now, she is basically a child again."

Shantel will need to be moved to an acute rehab facility, but her mother says because she had coronavirus - no facility has been willing to take her.

"Things were starting to pick up for her," her mother said. "I was so happy and so proud of her when she bought her first house. I was so proud of her when she got her degree, and I was like things are going so well for you and then (this)."

Wanavia has been off work because of the pandemic and has been doing what she can to scrape enough money together to care for Shantel's young son and prepare her home to care for her daughter, who won't be able to do anything for herself.

She has started a GoFundMe page to help offset some of the costs. Wanavia knows so many people are struggling right now, but says anything would be appreciated.

"As a parent you want the best for your kids and it is just hard when you see your kid struggling," she said. "She is very stubborn, very smart, very hard working. I am hoping and praying that thing about her that makes her so stubborn and such a fighter., will help her get past this."

Shantel said her first words today. If you would like to contribute, GO HERE.

View original post here:
Mother of 2 with diabetes gets coronavirus and is left with brain damage - FOX 2 Detroit

Read More...

Diabetic Retinopathy Appears Linked to Depression – Medscape

June 2nd, 2020 8:46 pm

People with diabetic retinopathy experience depression at higher rates than the general population, but the rate decreases at the most severe stage of the disease, an analysis of a large database shows.

Although the study did not establish cause and effect, it alerts clinicians to explore the ways that the emotional wellness of a patient might be intertwined with eye disease, said Daniel Olson, MD, from the University of North Carolina in Chapel Hill.

"I believe in treating the whole patient, not just the eyeball," he told Medscape Medical News.

Olson became interested in the mental health of patients with diabetic retinopathy when he noticed their reactions during conversations about the course of the disease. "You see the anxiety and sadness building up in these patients," he said.

Previous studies have established an association between the eye disease and depression and anxiety. But the number of patients in these studies was not large enough to look at the association between mental health and some key subgroups.

To fill this gap, Olson and his colleagues analyzed a database of 95,575 people 18 years and older with eye exams on record at the Carolina Data Warehouse, a repository of all patients seen in the University of North Carolina system.

The team identified all patients with diagnoses of diabetic retinopathy, anxiety, depression, or some combination of these diseases, between July 2008 and July 2018 using International Classification of Diseases (ICD) codes. In the study cohort, 57.1% of the patients were women, 23.5% had diabetes mellitus, and 4.5% had diabetic retinopathy.

Of those without diabetic retinopathy, 18.7% had anxiety and 20.4% had depression, which is consistent with rates in the general population, Olson reported during his virtual presentation at the Association for Research in Vision and Ophthalmology 2020 Annual Meeting.

Among those who had a diagnosis of diabetic retinopathy, 21.5% had anxiety and 33.0% had depression. The rate of depression was significantly higher in those with diabetic retinopathy than in the general population, but the difference in the rate of anxiety was not significant.

This study is retrospective and does not provide a causal link between diabetic retinopathy and depression or anxiety, Olson acknowledged. It's possible that people become depressed when they are diagnosed with an eye disease, or conversely that depressed people don't take good care of their health, so their diabetes worsens, which leads to diabetic retinopathy.

To see if disease severity is associated with these mood disorders, the researchers looked at disease subsets: mild, moderate, and severe nonproliferative diabetic retinopathy, and proliferative diabetic retinopathy.

The risk for depression was 98% higher in patients with severe nonproliferative disease than in those without diabetic retinopathy. However, risk for depression was just 41% higher in patients who had progressed to proliferative disease.

A similar trend emerged for anxiety; the risk was significantly elevated only in patients with mild diabetic retinopathy.

Olson offered two possible explanations for the decline in depression and anxiety seen in patients in the most advanced stage of their disease.

First, patients might struggle to improve their exercise and diet without seeing results in the early stages of the disease. Then, once they advance to the proliferative stage and begin receiving treatment, they might realize that the treatments are not as bad as they feared. "They can calm down and not be as anxious or depressed," he said.

Second, patients with poor access to healthcare might not get treatment for diabetic retinopathy until it becomes proliferative and starts to affect their vision. Even if they are depressed, they might not see a primary care doctor, so their depression would not be documented in the database.

But such possibilities are speculative because the study does not show causation, cautioned Rahul Khurana, MD, assistant clinical professor of ophthalmology at the University of California, San Francisco.

"It's an interesting question to explore, but I'm not sure how we put it in the clinic," Khurana told Medscape Medical News.

For now, the work has already influenced Olson's interactions with his patients. He works closely with his patients' primary care physicians, and he listens more carefully.

"Rather than rattling off a list of things to do, which can be overwhelming to patients, I talk to patients about real ways they control the disease, and listen to their concerns so I can put them at ease about the course of the illness," he explained.

The study also showed that younger patients are more likely to experience anxiety than older patients, and men are more likely to experience depression than women.

"One reason for this may be that men are more visual creatures and the prospect of losing vision weighs more heavily on them," Olson said.

He said he would like to take the research further, following patients treated for both diabetic retinopathy and depression to see if depression treatment affects their retinopathy.

He has also found a similar association between mental health and age-related macular degeneration, and is exploring whether the number of injections a patient receives has any effect on mental health.

Association for Research in Vision and Ophthalmology (ARVO) 2020 Annual Meeting.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

See the article here:
Diabetic Retinopathy Appears Linked to Depression - Medscape

Read More...

Diabetic Peripheral Neuropathy Market is Expected to Increase with a CAGR of 12% for the Study Period of 2017-2030: DelveInsight – P&T Community

June 2nd, 2020 8:46 pm

LAS VEGAS, June 2, 2020 /PRNewswire/ -- Diabetic Peripheral Neuropathy Market will increase because of the rising global burden of diabetes that is driving prevalence of diabetic neuropathy, advancement in early diagnosis as well as launch of the promising therapies which will positively impact DPN market.

DelveInsight added a new report titled "Diabetic Peripheral Neuropathy MarketInsights, Epidemiology, and Market Forecast-2030" to its portfolio.

Key Highlights from Diabetic Peripheral Neuropathy Market report are:

Request for sample pages to know more onDiabetic Peripheral Neuropathy Epidemiology and Market Forecast

Diabetic Peripheral Neuropathy is a painful condition that is caused by nerve damage from diabetes. It is a common prevalent complication in neurological damage of Type 1 and Type 2 diabetes.

There is a huge patient population pool affected by the disease; the Diabetic Peripheral Neuropathy market report covers the disease epidemiology that is segmented into Total Diagnosed Prevalent Cases of DPN, Total Prevalent Cases of Painful DPN and Gender-specific Prevalent cases of DPN in the 7MM from 2017 to 2030.

The total Painful Diabetic Peripheral Neuropathy Prevalent Cases were 3,857,945 in the United States in 2020. Also, females are more affected by the disease as compared to males for Diabetic Peripheral NeuropathyPrevalent in the US in 2020.

Click here to know more onDiabetic Peripheral Neuropathypipeline

Among the 7MM, the US accounts for 58% of the overall market size of DPN. Among the EU-5 countries, Germany accounts for the highest market size for DPN. Diabetic Peripheral Neuropathy market has a diverse pipeline with several promising therapies. Also, Gene therapy has been developed for DPN pain management. Of the emerging therapies, the most anticipated product to get launched is VM202 Apart from this, other products include VM202 (Helixmith), NYX-2925 (Aptinyx), WST-057 (4% pirenzepine) (WinSanTor, Inc.), Ricolinostat (Regenacy Pharmacuticals), NRD.E1 (Novaremed Ltd.), Cebranopadol (Grnenthal GmbH), GRC 17356 (Glenmark Pharmaceuticals), and others are also expected to enter the market by 2030 as effective therapies. The potential launch of these emerging drugs will aid in overall market growth. There are a couple of market drivers which will be driving the market. One such factor will be an early diagnosis of the DPN because of the advancements happening in the DPN diagnostic approaches. As the patient pool for diabetic peripheral neuropathy is quite large, and there is no treatment for reversal of disease, this indication withholds a plethora of opportunities for drug development companies. No doubt that the clinical pipeline contains a large number of drugs; however, previously multiple clinical trial failures gave a setback and limited the research and development in the DPN domain. So far it has been clear that path traversed is not easy in DPN research as the long-term clinical trials and low success rate in meeting the clinical endpoints may become threats for the investors to fund further.

There aremany key players robustly involved in developing potential drugs and they are a ray of hopefor DPN patients such as:1. VM2022. NYX-29253. WST-0574. Ricolinostat5. ISC 175366. NRD135S.E17. Cebranopadol8. GRC 173569. MEDI735210. Trazodone/GabapentinAnd many others

The key players involved in Diabetic Peripheral Neuropathy market are:1. Helixmith2. Aptinyx3. WinSanTor, Inc4. Regenacy Pharmacuticals5. Ichnos Science6. Novaremed7. Grnenthal GmbH8. Glenmark Pharmaceuticals9. AstraZeneca10. AngeliniAnd many others

The reasons for buying Diabetic Peripheral Neuropathy market report:

Table of contents

1. Key Insights

2. Executive summary

3. Diabetic Peripheral Neuropathy Market Overview at a Glance

4. Diabetic Peripheral Neuropathy Epidemiology and Market Methodology

5. Diabetic Peripheral Neuropathy Disease Background and Overview

6. Diabetic Peripheral Neuropathy Epidemiology and Patient Population

6.1. Key Findings

6.2. Total Diagnosed Prevalent cases of Diabetic Peripheral Neuropathy in 7MM

6.3. United States

6.4. EU5

6.5. Germany

6.6. France

6.7. Italy

6.8. Spain

6.9. United Kingdom

6.10. Japan

7. Diabetic Peripheral Neuropathy Treatment and Management

8. Diabetic Peripheral Neuropathy Unmet need

9. Diabetic Peripheral Neuropathy Marketed Drugs

9.1. Key cross competition

9.2. Qutenza: Grnenthal

9.3. Tarlige: Daiichi Sankyo

10. Diabetic Peripheral Neuropathy Emerging drugs

10.1. Key cross competition

10.2. VM202: Helixmith

10.3. NYX-2925: Aptinyx

10.4. WST-057: WinSanTor

10.5. Ricolinostat: Regenacy Pharmaceuticals

10.6. Cebranopadol: Grnenthal

10.7. ISC 17536: Ichnos Science

10.8. NRD135S.E1: Novaremed

10.9. MEDI7352: AstraZeneca

10.10. Trazodone/Gabapentin: Angelini

11. Diabetic Peripheral Neuropathy Market Size

11.1. Key Findings

11.2. Total Market Size of Painful Diabetic Peripheral Neuropathy in 7MM

11.3. Diabetic Peripheral Neuropathy Market Outlook: 7 MM

11.4. United States

11.5. EU5

11.6. Germany

11.7. France

11.8. Italy

11.9. Spain

11.10. United Kingdom

11.11. Japan

12. Diabetic Peripheral Neuropathy Reimbursement policies

13. Market Drivers

14. Market Barriers

15. SWOT Analysis

16. KOL Views

17. Diabetic Peripheral Neuropathy Case Report

18. A Case Report of Diabetic Peripheral Neuropathy

19. Bibliography

20. Appendix

21. Diabetic Peripheral Neuropathy Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

Request a WebEx Demo to get a walk-through of the Diabetic Peripheral Neuropathy Market Report:https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-market

Related Reports:

Diabetic Peripheral Neuropathy Epidemiology Forecast-2030 report delivers an in-depth understanding of the disease, historical, forecasted epidemiology trends of DPN in the 7 MM.

Diabetic Peripheral Neuropathy Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Diabetic Peripheral Neuropathy market.

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.

Contact us:

Shruti Thakurinfo@delveinsight.com+91-9650213330DelveInsight

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

Read the original here:
Diabetic Peripheral Neuropathy Market is Expected to Increase with a CAGR of 12% for the Study Period of 2017-2030: DelveInsight - P&T Community

Read More...

Two thirds of those with diabetes do not feel safe at work – The Diabetes Times

June 2nd, 2020 8:46 pm

Two thirds (67 per cent) of people with diabetes attending work do not feel safe, according to a new survey carried out among those with the condition.

More than half of respondents (54 per cent) to the Diabetes UK poll also say their employer is not enabling them to socially distance at work.

Since the lockdown started, the charity has seen unprecedented demand from people with diabetes seeking support on issues relating to employment and coronavirus through its helpline and support services.

The survey of almost 3,000 people with diabetes, revealed that almost half (45 per cent) of the people who are either currently at work, or are soon due to be returning to work outside of the home, reported not feeling confident in raising concerns about social distancing or safety at work with their employer.

The 3.9 million people diagnosed with diabetes in the UK are identified in the Governments list of clinically vulnerable groups, and the current advice is that people with diabetes should follow social distancing measures stringently, stay at home as much as possible, and minimise contact with those they do not live with.

A return to business as usual is not possible for people with diabetes, because of the lack of adequate safeguards from Government to ensure their safety Chris Askew

The new research also revealed that more than half of those working outside of home (57 per cent) do not know where they can get support from to resolve workplace safety issues.

A key element of the Governments recent employment guidance to protect workers, was the need for employers to carry out risk assessments for their employees, and make provisions to mitigate risk where it existed.

However Diabetes UKs survey found that this does not seem to be working in practice, as of those due to return to work, 60 per cent have not been consulted about a risk assessment that had been, or was in the process of being carried out, despite being in a clinically vulnerable group.

Diabetes UK does not believe the Governments employment guidance goes far enough to ensure safety at work for people with diabetes and those in other clinically vulnerable groups who are at increased risk of serious illness or death if they catch Coronavirus.

The charity is urgently calling for additional measures to ensure the safety of clinically vulnerable people at work.

Diabetes UKs Chief Executive Chris Askew said: A return to business as usual is not possible for people with diabetes, because of the lack of adequate safeguards from Government to ensure their safety.

With the new evidence on the increased risk for people with diabetes regarding COVID-19 Government must act now and review all the current guidelines and measures to keep people with diabetes and other clinically vulnerable groups safe. If lockdown continues to ease without specific and enforceable safeguards for people in clinically vulnerable groups in place, this pressure will only intensify further.

People with diabetes deserve to have their individual needs fully considered, with action taken to reduce any risk of coming into contact with the virus. A generic and catch-all assessment of workplace risks by employers does not go far enough and this evidence shows is not working in practice for people with diabetes.

The Government must ensure that employers take all the necessary measures to keep all employees safe, now and going forward if they are expected to attend work outside the home this includes clinically vulnerable people having a right to stay working from home if they do not feel safe.

Diabetes UK has written an open letter to the Secretary of State for Business, Energy and Industrial Strategy, urgently calling for more robust protections for clinically vulnerable workers and greater clarity for both employees and employers. The organisation is specifically calling for:

Photo by Ketut SubiyantofromPexels

Continued here:
Two thirds of those with diabetes do not feel safe at work - The Diabetes Times

Read More...

One in ten with diabetes die within week of COVID-19 hospitalization: Weight a key factor – Clinical Daily News – McKnight’s Long Term Care News

June 2nd, 2020 8:46 pm

More than 10% of people with diabetes and COVID-19 receive ventilator intubation and die within a week of hospitalization, say investigators. Higher body weight is independently linked to these outcomes, while glucose control is not, they report.

Diabetes is a known contributor to COVID-19 severity, but the characteristics that predict adverse outcomes in diabetes patients have been unclear, wrote Bertrand Cariou, M.D., Ph.D., from the University of Nantes, France. In a new study, Cariou and colleagues found that 10.6% of 1,317 participants died within seven days of hospital admission. And the higher a patients body mass index, the greater their risk.

A number of other factors also predicted seven-day mortality at admission. These included labored breathing, lymphocyte (white blood cell) count levels, and the presence of inflammation and liver damage markers.

In contrast, factors that had no significant bearing on seven-day intubation and mortality included age, sex, long-term glucose control, chronic complications, and hypertension or usual medications.

Only BMI turned out to be independently associated with the primary outcome, Cariou wrote. Each increase in BMI is associated with an increase in the risk of intubation and/or death in the seven days following admission for COVID-19. So lets target this population as a really important population to keep social distancing and stay alert on avoiding the virus.

The study was published Friday in the journal Diabetologia.

Go here to read the rest:
One in ten with diabetes die within week of COVID-19 hospitalization: Weight a key factor - Clinical Daily News - McKnight's Long Term Care News

Read More...

Impacts of COVID 19 on the Global Regenerative Medicine Market Size: Global Industry Analysis, Growth, Top Companies Revenue, MRFR Reveals Insights…

June 2nd, 2020 8:45 pm

(MENAFN - GetNews) Market Research Future (MRFR) collected data on several factors including implications of COVID 19 Impact on Regenerative Medicine Market and demographic challenges, showed how it could move forward in the coming years.

Regenerative Medicine Market Outlook

Global regenerative medicine market is growing continually, witnessing a massive uptake. Market growth primarily attributes to the increasing advancement in healthcare technology and the growing prevalence of chronic diseases. Besides, improvements in the field of regenerative medicine and stem cell technology drive the growth of the market excellently.

Moreover, the rising uptake of therapeutics such as stem cell biology, cellular therapy, tissue engineering in applications, including cord blood, oncology, urology, orthopedics, neurology, dermatology, and others accelerate the market growth. According to Market Research Future (MRFR), the global regenerative medicine market is poised to grow at 25.4% CAGR throughout the forecast period (2016 2022).

Get a FREE Sample (Including COVID19 Impact Analysis, Full TOC, Tables and Figures) ofRegenerative Medicine Market@ https://www.marketresearchfuture.com/sample_request/2220

Additionally, the rising uptake of stem cell & tissue engineering processes in the treatment of health issues ranging from orthopedics, musculoskeletal & spine, dental, and skin/integumentary to cancer, neurology, and cardiology substantiate the market growth. Furthermore, the increasing rate of road accidents, injuries, and trauma cases drive the market exponentially, driving the demand for transplants & surgical reconstruction procedures.

On the other hand, factors such as the lack of awareness, skilled professionals, and stringent regulatory policies are projected to act as significant impeders for market growth. Nevertheless, funding support for the development of regenerative medicines would support the growth of the market throughout the predicted period. Also, widening application areas of regenerative medicines in the field of stem cell reconstructive and skin grafting would increase the market growth.

Global Regenerative Medicine Market Segments

The analysis is segmented into four dynamics;

By Material : Synthetic Materials, Genetically Engineered Materials, Pharmaceuticals, and others.

By Therapy : Stem Cell Biology, Cellular Therapy, Tissue Engineering, and others.

By Application : Cord Blood, Oncology, Urology, Orthopedics, Neurology, Dermatology, and others.

By Regions : Americas, Europe, Asia Pacific, Middle East & Africa, and Rest-of-the-World.

Regenerative Medicine Market Regional Analysis

North America is projected to continue dominating the global regenerative medicine market throughout the forecast period. In 2015, North America accounted for more than 44% of the overall market share. This huge market growth attributes to the presence of a large number of major players and pharma & biotechnology companies. Moreover, huge investments made by public & private organizations drive the regenerative medicine industry in the region.

Besides, the rising prevalence of chronic diseases and orthopedic issues and increasing clinical trials to evaluate the therapeutic potential of products foster regional market growth. Also, the well-spread awareness towards the therapeutic potency of regenerative medicines impacts the market growth positively. The North American regenerative medicine market is expected to grow at a robust CAGR of 22.3% over the review period.

Europe stands second in the global regenerative medicine market. Factors such as the increasing per capita healthcare expenses and penetration of healthcare sectors in the region boost the market growth. Additionally, the rising government support and R & D funding in the life science developments substantiate the regional market growth. Markets in the UK, Germany, and France, contribute to the regional market majorly. The European regenerative medicine market is estimated to grow at 22.5% CAGR during the assessment period.

The Asia Pacific regenerative medicine market has emerged as a rapidly growing market. Factors such as the large advances in biotechnology and increasing government support for R & D are fostering the growth of the regional market. Regenerative medicine markets in highly populated countries such as China, India, and Japan support the regional market growth excellently, heading with huge technological advances. The APAC Regenerative Medicine market is predicted to demonstrate huge growth potential.

Global Regenerative Medicine Market - Competitive Analysis

The well-established regenerative medicine market appears to be highly competitive with the presence of several notable players. To gain a larger competitive advantage, market players incorporate strategic initiatives such as mergers & acquisitions, expansions, and product/technology launch. Also, they make substantial investments to drive R & D to develop their capabilities and to expand their global footprints. Simultaneously, R & D funding programs initiated by the governments to enhance regenerative medicine capabilities are offering high growth potential. This is further going to attract several new entrants to the market and intensify the market competition further.

Regenerative Medicine Market Major Players:

Players active in the global regenerative medicine market include Osiris Therapeutics, Cook Biotech, Organogenesis, Baxter International, Inc., Stryker and RTI surgical, LifeSciences, CryoLife, Advanced Cell Technology, Sanofi, BioMimetic Therapeutics, Medtronic, StemCellsInc, and LifeCell Kinetic Concepts, among others.

Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/regenerative-medicine-market-2220

Regenerative Medicine Industry/Innovations/Related News:

March 15, 2020 - Research team at the University of Sheffield published their study on stem cell mutations that could improve regenerative medicine in the magazine Stem Cell Reports.' Their study gives new insights into the cause of mutations in pluripotent stem cells and potential ways of stopping these mutations from occurring. It also suggests ways to reduce the likelihood of variations occurring in these cells when cultured.There is considerable interest in using Pluripotent stem cells to produce cells that can replace diseased or damaged tissues in applications referred to as regenerative medicine.

Pharmaceutical Industry Related Reports

Global Anti-viral drugs Market Information, by application (hepatitis, HIV/AIDS, herpes, influenza and others) and by mechanism of action (nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors and others) - Forecast to 2022: https://www.marketresearchfuture.com/reports/anti-viral-drugs-market-2454

Drug allergy market information: by type (immunologic, nonimmunologic, and others), diagnosis (skin tests, blood tests, and others), by treatment (antihistamines, corticosteroids, and others), by end user- global forecast till 2023: https://www.marketresearchfuture.com/reports/drug-allergy-market-4033

About Market Research Future:

At Market Research Future (MRFR) , we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

NOTE: Our team of researchers are studying Covid-19 and its impact on various industry verticals and wherever required we will be considering covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

Media Contact Company Name: Market Research Future Contact Person: Abhishek Sawant Email: Send Email Phone: +1 646 845 9312 Address: Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar City: Pune State: Maharashtra Country: India Website: http://www.marketresearchfuture.com/reports/regenerative-medicine-market-2220

MENAFN0206202000703268ID1100263430

Go here to see the original:
Impacts of COVID 19 on the Global Regenerative Medicine Market Size: Global Industry Analysis, Growth, Top Companies Revenue, MRFR Reveals Insights...

Read More...

Exceptional stem cell science on tap for ISSCR 2020 Virtual June 23-27, 2020 – 7thSpace Interactive

June 2nd, 2020 8:45 pm

Exceptional stem cell science on tap for ISSCR 2020 Virtual June 23-27, 2020

Skokie, IL - The International Society for Stem Cell Research has transformed its annual scientific meeting into a virtual experience, bringing the global stem cell community together to share knowledge, collaborate, and network. Attendee registration and complementary media registration are open!

The ISSCR 2020 Virtual Meeting, cosponsored by the Harvard Stem Cell Institute (HSCI), will deliver a comprehensive scientific education program that includes plenaries featuring world-renowned scientists in the field. Following are some highlights of the program:

New Session: ISSCR Response to COVID-19 Featuring Opening Address by Dr. Anthony Fauci, Director, National Institute for Allergy and Infectious Diseases, USA

The COVID 19 pandemic has mobilized the global scientific and clinical communities from across disciplines. This collective effort is essential to understand the biology of the novel coronavirus infection process, the resulting clinical pathology and develop potential treatments, including a vaccine. In this session, the ISSCR brings together leading scientists to discuss the latest research and clinical findings in this rapidly moving field. Speakers to be announced soon!

Clinical Innovation and Gene Editing Sponsored by BlueRock Therapeutics

Patient Advocate Address: Matthew Might, University of Alabama at Birmingham, USA

John McNeish Lecture: Brian Wainger, Harvard University, USA Katherine High, Spark Therapeutics, USA Michel Sadelain, Memorial Sloan-Kettering Cancer Center, USA

Keynote Address: Sekar Kathiresan, Verve Therapeutics, USA

Which new cell therapies will progress to the clinic this year? Learn about the cutting-edge advances propelling regenerative medicine forward. Leading scientists will share their latest data on the use of stem cells to treat diseases from ALS to heart disease, and from blindness to cancer. This session will explore the stem cell engineering, gene editing, and precision medicine approaches that are advancing stem cell therapies.

Presidential Symposium Sponsored by: Fate Therapeutics

Ernest McCulloch Lecture: Fiona Watt, King's College London, UK Steven Finkbeiner, Gladstone Institutes, USA Eric Olson, University of Texas Southwestern, USA Aviv Regev, Broad Institute, USA

Each year the current ISSCR president assembles speakers who highlight some of the most exciting work in stem cell biology. In this year's Presidential Symposium, Deepak Srivastava brings together researchers that span many key topics in the field. Attendees will explore foundational topics such as self-renewal, lineage commitment, transcriptional regulation, and tissue maintenance as well as multi-disciplinary topics such as how biological circuits function and evolve or how neuronal activity leads to memory.

Machine Learning and Computational Approaches Sponsored by: T-CiRA Joint Program

ISSCR Dr. Susan Lim Outstanding Young Investigator Award Lecture: Allon Klein, Harvard Medical School, USA Trey Ideker, University of California, San Diego School of Medicine, USA Ajamete Kaykas, insitro, USA Hiroaki Kitano, Okinawa Institute of Science and Technology, Japan Emma Lundberg, KTH Royal Institute of Technology, Sweden

Machine learning and computational approaches are revolutionizing all fields of biology. These constantly evolving technologies provide new windows into stem cell population dynamics, heterogeneity, and clonality. Researchers also use computational modeling to improve the translation of stem cell science, including methods to investigate disease states, predict drug targeting, and develop the proper conditions for stem cell expansion and differentiation. Discover the newest techniques and approaches are applied to stem cell science and gain insights that you can adapt to your research.

Embryogenesis and Development Sponsored by: Semma Therapeutics

Benoit Bruneau, Gladstone Institutes, USA Elaine Fuchs, HHMI, Rockefeller University, USA Ken Zaret, University of Pennsylvania School of Medicine, USA Kathy Niakan, The Francis Crick Institute, UK

Stem cell scientists constantly unravel and expose the mysterious embryo development process. Leading innovators will dissect the earliest decisions in the mammalian embryo, decode the genetic regulation that leads to specific cell and tissue identity, and uncover what happens when these developmental programs go awry. These presentations will explore developmental principles that are fundamental to all parts of stem cell biology.

Stem Cells and Aging

ISSCR Tobias Award Lecture: Margaret Goodell, Baylor College of Medicine, USA Guanghui Liu, Institute of Biophysics, CAS, China Emi Nishimura, Tokyo Medical and Dental University, Japan Michael Rudnicki, Ottawa Hospital Research Institute, Canada Beth Stevens, Boston Children's Hospital, USA

Stem cell function often is dramatically affected during aging. Understanding these processes may help scientists determine how to prevent degeneration. Through the presentations, the decline in stem cell frequency and function that often accompanies the aging process will be explored. Attendees will gain new knowledge about principles unique to specific tissues, or common between all, and how misregulation of stem cells plays a key role in aging and disease.

Dissecting Organogenesis Sponsored by: Semma Therapeutics

ISSCR Momentum Award Lecture: Mitinori Saitou, Kyoto University, Japan Miki Ebisuya, EMBL Barcelona, Spain Madeline Lancaster, MRC Laboratory of Molecular Biology, UK Hans Snoeck, Columbia University Medical Center, USA

Novel techniques allow scientists to examine mechanisms of morphogenesis and differentiation during in vivo and in vitro organogenesis. Attendees will discover how researchers apply interdisciplinary approaches from epigenetic reprogramming to synthetic biology to organoids in order to dissect the cellular and molecular mechanisms of organogenesis. Additionally, attendees will hear about new translational studies that are bringing this research to the clinic and comparative studies that explain what makes humans unique.

Reprogramming and Regeneration Sponsored by FujiFilm

ISSCR Achievement Award Lecture: Fred H. Gage, Salk Institute for Biological Studies, USA

Anne McLaren Lecture: Alta Charo, University of Wisconsin USA Botond Roska, Friedrich Miescher Institute, Switzerland Li Qian, University of North Carolina, Chapel Hill, USA Shinya Yamanaka, Center for iPS Cell Research & Application, Japan

Reprogramming and regeneration are essential focal points in the study of stem cell biology. Leading researchers will illuminate the current state of these topic areas and how they are advancing stem cell therapies from bench to bedside. Attendees will hear about how reprogrammed cells are helping us understand disease and screen for new drugs, new insights into the mechanisms of regeneration, and the ethical issues surrounding it all.

Not only will ISSCR 2020 host outstanding plenaries, but also concurrent programming sessions organized around four core themes covering areas of the field. The meeting will host workshops from industry leaders on clinical translation, and biotech entrepreneurs discussing new ventures and investment. Special sessions cover public policy, women in science, science and ethics, stem cell technology, and preclinical development of investigational stem cell products. See speakers and sessions.

The ISSCR 2020 Virtual Meeting will feature live Q&A, networking hubs, a digital poster hall, and a vibrant, virtual exhibit floor. Attendees can access on-demand viewing of all sessions 24 hours-a-day for 30 days. All networking and professional development workshops and special sessions are now included with registration. Learn more about the high-caliber speakers and explore the workshops and special sessions that are incorporated into the virtual meeting this year.

###

Registration is open. Complementary registration is available for media; apply for credentials. To connect for interviews, contact Kym Kilbourne at kkilbourne@isscr.org or media@isscr.org.

About the International Society for Stem Cell Research

With nearly 4,000 members from more than 60 countries, the International Society for Stem Cell Research is the preeminent global, cross-disciplinary, science-based organization dedicated to stem cell research and its translation to the clinic. The ISSCR mission is to promote excellence in stem cell science and applications to human health. Additional information about stem cell science is available at A Closer Look at Stem Cells, an initiative of the Society to inform the public about stem cell research and its potential to improve human health.

This story has been published on: 2020-06-02. To contact the author, please use the contact details within the article.

See the original post here:
Exceptional stem cell science on tap for ISSCR 2020 Virtual June 23-27, 2020 - 7thSpace Interactive

Read More...

Orthopedic Joint Replacement Market to Gain Traction; Rising Prevalence of Bone Diseases to Boost Growth, states Fortune Business Insights -…

June 2nd, 2020 8:45 pm

Pune, June 01, 2020 (GLOBE NEWSWIRE) -- The global orthopedic joint replacement market size is predicted to reach USD 26,967.9 million by 2026 exhibiting a CAGR of 5.1% during the forecast period. The increasing prevalence of bone diseases among the geriatric population will bolster healthy growth of the market during the forecast period, states Fortune Business Insights in a report, titled Orthopedic Joint Replacement Market Size, Share and Industry Analysis By Product (Knee, Hip, Shoulder, Ankle, Others), By Procedure (Total Replacement, Partial Replacement, Others), By End User (Hospital, Ambulatory Surgical Centers, Orthopedic Clinics, Others), and Regional Forecast 2019-2026 the market size stood at USD 19,051.2 million in 2018. The rising cases of osteoarthritis will spur opportunities for the market in the foreseeable future.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/orthopedic-joint-replacement-market-100314

Market Driver:

Advent of Robotic Surgery to Aid Robust Development

The growing demand for orthopedic joint implants will provide an impetus to the market. The adoption of robotic surgery and patient-specific 3-D printed implants will have a tremendous impact on the global market during the forecast period. The rising favorable reimbursement policies will favor the healthy growth of the market during the forecast period. in 2017, the Centers for Medicare and Medicaid Services added coverage of US$ 10,122.0 for outpatient total knee replacement procedures. The growing government initiatives will encourage the healthy growth of the market during the forecast period. The growing surgeries for knee replacement will impel companies to introduce innovative products for the prevailing incidents.

For instance, the release of ATTUNE Revision Knee System, Persona Partial Knee System, JOURNEY II XR Total Knee, and others by major players will positively influence the growth of the market. Furthermore, the shoulder segment is predicted to account for the lions share during the forecast period. The rising emphasis on the development of innovative shoulder implants by key manufacturers will accelerate the segments growth. The surge in the number of shoulder replacement surgeries can be a vital factor in propelling the growth of the market. In addition, the rising acceptance of joint replacement solutions by orthopedics will consequently create opportunities for the market in the forthcoming years.

An Overview of the Impact of COVID-19 on this Market:

The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.

We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

To get the short-term and long-term impact of COVID-19 on this Market.

Please visit: https://www.fortunebusinessinsights.com/industry-reports/orthopedic-joint-replacement-market-100314

Regional Analysis:

Propitious Reimbursement Policies to Boost Growth in North America

The market in North America is likely to account for the lions share during the forecast period owing to the rising demand for joint implants. The favorable reimbursement policies along with rising replacement surgeries in outpatient settings will contribute to the growth of the market in North America. Europe is expected to rise tremendously during the forecast period owing to the growing number of joint replacement procedures.

The emergence of domestic manufacturers will have a positive impact on the European market. Asia Pacific is likely to witness an exponential growth rate due to the increase in orthopedic clinics. The rapid adoption of orthopedic products and active government support will encourage growth in the region. Nonetheless, the growing incidence of osteoarthritis in patients will promote the growth of the market in the region. In addition, the rising geriatric population will further enhance growth in the Asia Pacific.

Quick Buy - Orthopedic Joint Replacement Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100314

Key Development:

August 2019:Globus Medical announced that it has signed an agreement with StelKast, one of the manufacturers of knee and hip implants.

March 2018:Smith & Nephew announced the release of bi-cruciate retaining JOURNEY II XR total knee arthroplasty (TKA) in the U.S and Japan.

List of Key Companies Operating in the Orthopedic Joint Replacement Market are:

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/orthopedic-joint-replacement-market-100314

Detailed Table of Content:

TOC Continued.!

Request for Customization: https://www.fortunebusinessinsights.com/enquiry/customization/orthopedic-joint-replacement-market-100314

Have a Look at Related Reports:

Orthobiologics Market Size, Share and Global Trend by Product Type (Viscosupplements, Bone Growth Stimulators, Demineralized Bone Matrix, Synthetic Bone Substitutes, Stem Cells, Allografts), Application (Spinal Fusion, Maxillofacial & Dental, Soft Tissue Repair, Reconstructive & Fracture Surgery), End User (Hospitals, Ambulatory Surgical Centers, Speciality Clinics) and Geography Forecast till 2025

Bone Growth Stimulators Market Size, Share and Global Trend By Product Type (Bone Growth Stimulation Devices, Bone Morphogenetic Proteins (BMP), Platelet-Derived Growth Factor (PDGF)), By Application (Spinal Fusion, Maxillofacial & Dental, Nonunion and Union Bone Fractures), By End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Home Care), and Geography Forecast till 2026

Bone Morphogenetic Proteins Market Size, Share and Global Trend By Type (rhBMP-2, rhBMP-7, Others), By Application (Spinal Fusion, Trauma Surgery, Reconstructive Surgery, Maxillofacial & Dental), and Geography Forecast till 2026

Bone Void Fillers Market Size, Share and Global Trend By Material Type (Demineralized Bone Matrix, Collagen Matrix, Calcium Sulphate, Hydroxyapatite, Tri-Calcium Phosphate, Others), By Forms (Gel, Granules, Putty, Paste, Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others) and Geography Forecast till 2026

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.

Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: sales@fortunebusinessinsights.comFortune Business InsightsLinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/orthopedic-joint-replacement-market-9111

View post:
Orthopedic Joint Replacement Market to Gain Traction; Rising Prevalence of Bone Diseases to Boost Growth, states Fortune Business Insights -...

Read More...

Coming Together to Solve COVID-19 Mysteries | University of Pennsylvania Almanac – UPENN Almanac

June 2nd, 2020 8:45 pm

Coming Together to Solve COVID-19 Mysteries

As the COVID-19 pandemic began to be felt, scientists at Penn started work todevelop a vaccineandassess possible treatments. But the scope of COVID-19 studies at the University goes much broader. Scientists whose typical work finds them investigating autoimmune disease, influenza, HIV/AIDS, Ebola, cancer, hemophilia and more, are now applying their deep understanding of biology to confront a novel threat.

What Does SARS COVID-19 Do To Our Lungs? Another respiratory infection, influenza, has been a focus of research led by Andrew Vaughan, Penn Vet assistant professor of biomedical sciences. But Dr. Vaughan didnt hesitate to begin studies of the novel coronavirus once its eventual impact became apparent. Now, graduate students and research specialists in his labworking no more than two together at a time to maximize social distancingare conducting new experiments focused more specifically on the biology of SARS-CoV-2, alongside parallel efforts by Edward Morrissey from PSOM. Knowing that the ACE2 receptor on lung cells is the gateway for the virus into the human body, theyre genetically manipulating alveolar type-two lung cells, which are particularly essential for continuing oxygen exchange deep in the lungs, to alter or block ACE2 gene expression to try to prevent viral entry.

Why are Men Worse Off Than Women? In a separate project, Dr. Vaughan is partnering with Montserrat Anguera, Penn Vet associate professor of biomedical sciences, to explore a curious feature of COVID-19 disease: the fact that more men than women become severely ill and die. A number of hypotheses have been put forward to explain the disparity, but the two labs are investigating one particular possibility.

Dr. Anguera had posted something on Twitter saying that the ACE2 gene happens to be on the X chromosome, meaning that women have two copies of it, said Dr. Vaughan. I immediately texted her and said, I think theres something to that.

Hormone expression levels are another factor that may influence sex differences in disease. Together, Drs. Anguera and Vaughans groups are both studying ACE2 expression and exposing alveolar type-two cells to various hormones to see how expression of viral receptors, ACE2 and others, changes. Ultimately wed like to see if this changes susceptibility to infection, working withSusan Weissand others, said Dr. Vaughan.

Do Genetics Influence Susceptibility? Individual differences in how people respond to infection may be influenced by their unique genomic sequences. PIK Professor Sarah Tishkoff of PSOM and SAS is probing the rich sources of genomic data her group already had in hand to look for patterns that could explain differences in disease susceptibility. Using genomic data from 2,500 Africans collected for another project, Dr. Tishkoffs team is looking for patterns of genetic diversity. Early findings suggest that natural selection may have acted upon on a version of the ACE2 gene, making it more common in some African populations with high exposure to animal viruses.

She is also collaborating withAnurag Vermaand Giorgio Sirugo of Penn Medicine to analyze genetic variation in samples from thePenn Medicine Biobank, looking in particular at people of African descent.

How is the Immune System Reacting? The immune system is what eliminates the virus, saidE. John Wherry, chair of Systems Pharmacology and Translational Therapeutics at PSOM. The immune system is what we need to activate with a good vaccine. But also, especially in many respiratory infections, the immune system is what also causes damage. A healthy outcome means your immune system is striking a balance between killing off the virus and not doing so much damage that it kills you.

Dr. Wherry and Michael Betts, professor of microbiology, have embarked on a study to discern both the magnitude of patients immune responses as well as their flavor, that is, what components in the immune system are being activated by the coronavirus. They are doing so by working with clinicians at HUP and, soon, atPenn Presbyterian Medical Center, to collect blood samples from patients with severe and more mild infections, as well as patients who have recovered from illness, to profile their immune reactions. Variety across patients strongly suggests that the treatments that work for one patient may not for another, Drs. Wherry and Betts note. They are speaking daily with their colleagues on the front lines of COVID-19 care, relaying what theyre finding out in the lab.

The PSOMs Ronald Collman, professor of medicine, andFrederic Bushman, William Maul Measey Professor in Microbiology, have been devoting attention to how the community of bacteria, viruses, fungi and parasites that dwell in the respiratory tract affect health and disease risk. They are now addressing that question in the context of COVID-19. According to Dr. Collman, The microbiome can help set the tone for the immune response to infections, influencing whether a patient ends up with mild or severe disease. And second, the microbiome is where infectious agents that can cause infection can arise from. So if a patient dies of an eventual pneumonia, the pathogen that caused that pneumonia may have been part of that individuals respiratory tract microbiome.

Working with nurses at HUP to collect samples, Drs. Collman and Bushman are analyzing the microbiome of both the upper and lower portions of the respiratory tract of COVID-19 patients. Their labs are using these samples to identify the types and quantities of organisms that compose the microbiome to find patterns in how they correlate with disease.

What Drugs Might Make An Impact? Absent a vaccine, researchers are looking to existing drugssome already approved by the US FDA for other maladiesto help patients recover once infected. Throughout his career,Ronald Harty, Penn Vet professor of pathobiology and microbiology, has worked to develop antivirals for other infections, such as Ebola, Marburg and Lassa Fever.

Though many of the biological details of how SARS-CoV-2 interacts with the human body are distinct from the other diseases Dr. Harty has studied, his group noticed a similarity: A sequence hes targeted in other virusesa motif called PPxYis also present in the spike protein of SARS-CoV-2, which the coronavirus uses to enter cells.

This caught our eye, said Dr. Harty, and piqued our interest in the very intriguing possibility that this PPxY motif could play a role in the severity of this particular virus. He is testing antivirals he has helped identify that block the replication of Ebola, Marburg and other viruses to see if they make a dent on the activity of SARS-CoV-2. Those experiments will be done in collaboration with colleagues whose labs can work in BSL-III or -IV laboratories.

Also of interest is the speculation that the coronavirus might disrupt cell-cell junctions in the human body, making them more permeable for virus spread.

Another faculty member is assessing whether a drug developed for a very different conditionpulmonary arterial hypertension(PAH)could serve coronavirus patients. Henry Daniell, vice-chair and W.D. Miller Professor in Penn Dentals department of basic and translational sciences, shared news that a drug grown in a plant-based platform to boost levels of ACE2 and its protein product, angiotensin (1-7), was progressing to the clinic to treat PAH. Dr. Daniell is now working withKenneth Margulies, PSOM professor of medicine and physiology and research and fellowship director of the Heart Failure and Transplant Program, to explore whether this novel oral therapy can improve the clinical course of patients with symptomatic COVID-19 infection.

Reduced ACE2 expression has been linked to acute respiratory distress, severe lung injury, multi-organ failure and death, especially in older patients. The earlier preclinical studies in PAH animal models showed that orally delivered ACE2 made in plant cells accumulated ten times higher in the lungs than in the blood and safely treated PAH. Now, new clinical studies have been developed to explore whether oral supplementation of ACE2 and angiotensin-1-7 can help mitigate complications of COVID-19 disease. The fact that freeze-dried plant cells can be stored at room temperature for as long as a year and can be taken at home by COVID-19 patients make this novel approach an attractive potential option.

This trial has been given a high priority by the Penn Clinical Trial Working Group, said Dr. Daniell. Im pleased that this looks to be on the cusp of moving forward to help the growing number of COVID-19 patients.

As the coronavirus began to spread in the US, Joshua Plotkin, Walter H. and Leonore C. Annenberg Professor of the Natural Sciences, began to raise alarms about Philadelphias St. Patricks Day parade. His studies of the 1918 flu pandemic had explored disease incidence and spread, and it was hard to avoid noticingthe role of the Liberty Loan paradedown Broad Street in triggering a rampant spread of flu back then. Now, with work conducted with two graduate students and faculty member Simon Levin fromPrinceton University, Dr. Plotkin has mathematically sound advice for policymakers hoping to effectively stem the spread of a pandemic. In apreprint on arXiv.org, they share optimal, near-optimal, and robust strategies.

Their analysis makes the realistic assumption that policymakers can only enforce social distancing for a limited amount of time and aims to minimize the peak incidence of disease. The optimal strategy, they found, is to start by introducing moderate social distancing measures to keep the incidence rate the same for a period of time. This would mean that every person with COVID-19 would infect one additional person. Then the intervention should switch over to a full suppressionthe strongest possible quarantinefor the rest of the period. At the end of that period, all restrictions would be lifted.

This works because you dont want to fully suppress disease spread right off the bat, said Dr. Plotkin, because then at the end, after you remove restrictions, there will be a second peak that is just as large as the first. By employing a moderate suppression at the beginning, youre building up a population of people who are going to recover and become immune, without letting the epidemic get out of control.

Dr. Plotkin and colleagues are hoping to share the findings widely to help navigate a likely second wave of COVID-19.

Adapted from a story by Katie Baillie, Penn TodayVisithttps://tinyurl.com/pennandcovid for the full story.

See the original post here:
Coming Together to Solve COVID-19 Mysteries | University of Pennsylvania Almanac - UPENN Almanac

Read More...

Integrative Medicine in Child Neurology: What Do Physicians Know and What Do They Want to Learn? – Physician’s Weekly

June 2nd, 2020 8:44 pm

Pediatric neurology patients frequently use integrative medicine; however, providers may feel uncomfortable or unfamiliar with these therapies. Child neurologist attitudes toward integrative medicine and educational needs in integrative medicine have not been assessed. A national, anonymous survey was distributed to Child Neurology residents (n=294) and program directors (n=71) to assess attitudes toward specific integrative medicine modalities, practices in discussing integrative medicine with patients, and perceived need for a curriculum on integrative medicine; 61 (17%) partially and 53 (15%) fully completed the survey. Comparative analyses applied chi-square and independent tests. Qualitative content analysis was performed on free text responses. Most providers surveyed consider mind and body practices safe (93% of respondents) and effective (84%), but have concerns about the safety of chiropractic manipulation (56% felt this was harmful), and the efficacy of homeopathy (none considered this effective). Few inquire about patient integrative medicine use regularly. Child Neurology residents are interested in further education on this topic.

PubMed

See the original post here:
Integrative Medicine in Child Neurology: What Do Physicians Know and What Do They Want to Learn? - Physician's Weekly

Read More...

Page 517«..1020..516517518519..530540..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick